Active	Status	Sponsor type	Region	Phase	Filter
8 Active 1 Inactive 9 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes: « April » « 2025 » M T W T F S S 31 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 1 2 3 4   - « April » « 2025 » M T W T F S S 31 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 1 2 3 4   Show only changed items Enrollment:

Advanced Filters

8 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Furihata, Kenichi
TRAILRUNNER-ALZ 3, NCT06653153: A Study of Remternetug (LY3372993) in Early Alzheimer's Disease	Recruiting	3	1200	Europe, Canada, Japan, US, RoW	Remternetug, LY3372993, Placebo	Eli Lilly and Company	Alzheimer's Disease	04/29	10/30
NCT05026866: A Donanemab (LY3002813) Study in Participants With Preclinical Alzheimer's Disease (TRAILBLAZER-ALZ 3)	Recruiting	3	2196	Japan, US	Donanemab, LY3002813, Placebo	Eli Lilly and Company	Alzheimer Disease	11/27	11/27
NCT06297616: A Study of LY3841136 in Japanese Participants With Obesity or Overweight	Recruiting	1	128	Japan	LY3841136, LY3841136-Placebo, Tirzepatide, Tirzepatide-Placebo	Eli Lilly and Company	Obesity, Overweight	11/25	11/25
NCT05486208: A Study of LY3844583 in Healthy Participants and Participants With Atopic Dermatitis	Terminated	1	102	Japan, US	LY3844583, Placebo	Eli Lilly and Company	Healthy, Dermatitis, Atopic	01/24	01/24
NCT05395481: A Single-Ascending and Repeated Dose Study of LY3849891 in Participants with Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)	Recruiting	1	176	Japan, US	LY3849891, Placebo	Eli Lilly and Company	Metabolic Dysfunction-Associated Steatohepatitis (MASH), Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD)	10/26	10/26
NCT06869018: A Study of LY3549492 in Japanese Participants with Type 2 Diabetes Mellitus (T2D) and Healthy Japanese Participants	Not yet recruiting	1	90	Japan	LY3549492, Placebo	Eli Lilly and Company	Healthy, Type 2 Diabetes Mellitus (T2D)	02/26	02/26
NCT06119529: A Study of LY3872386 in Healthy Participants and Participants With Atopic Dermatitis	Terminated	1	18	US	LY3872386, Prednisone, Placebo	Eli Lilly and Company	Healthy, Atopic Dermatitis	04/24	04/24
NCT05569005: Effect of Switching From Cigarette Smoking to THS on Disease Progression in Mild to Moderate COPD Subjects With Chronic Bronchitis Symptoms.	Terminated	N/A	715	Europe, Japan, US, RoW	THS use, Tobacco Heating System 3.0, Cigarette, Smoking Abstinence	Philip Morris Products S.A.	COPD, Smoking, Tobacco Use	09/24	09/24

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Furihata, Kenichi
TRAILRUNNER-ALZ 3, NCT06653153: A Study of Remternetug (LY3372993) in Early Alzheimer's Disease	Recruiting	3	1200	Europe, Canada, Japan, US, RoW	Remternetug, LY3372993, Placebo	Eli Lilly and Company	Alzheimer's Disease	04/29	10/30
NCT05026866: A Donanemab (LY3002813) Study in Participants With Preclinical Alzheimer's Disease (TRAILBLAZER-ALZ 3)	Recruiting	3	2196	Japan, US	Donanemab, LY3002813, Placebo	Eli Lilly and Company	Alzheimer Disease	11/27	11/27
NCT06297616: A Study of LY3841136 in Japanese Participants With Obesity or Overweight	Recruiting	1	128	Japan	LY3841136, LY3841136-Placebo, Tirzepatide, Tirzepatide-Placebo	Eli Lilly and Company	Obesity, Overweight	11/25	11/25
NCT05486208: A Study of LY3844583 in Healthy Participants and Participants With Atopic Dermatitis	Terminated	1	102	Japan, US	LY3844583, Placebo	Eli Lilly and Company	Healthy, Dermatitis, Atopic	01/24	01/24
NCT05395481: A Single-Ascending and Repeated Dose Study of LY3849891 in Participants with Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)	Recruiting	1	176	Japan, US	LY3849891, Placebo	Eli Lilly and Company	Metabolic Dysfunction-Associated Steatohepatitis (MASH), Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD)	10/26	10/26
NCT06869018: A Study of LY3549492 in Japanese Participants with Type 2 Diabetes Mellitus (T2D) and Healthy Japanese Participants	Not yet recruiting	1	90	Japan	LY3549492, Placebo	Eli Lilly and Company	Healthy, Type 2 Diabetes Mellitus (T2D)	02/26	02/26
NCT06119529: A Study of LY3872386 in Healthy Participants and Participants With Atopic Dermatitis	Terminated	1	18	US	LY3872386, Prednisone, Placebo	Eli Lilly and Company	Healthy, Atopic Dermatitis	04/24	04/24
NCT05569005: Effect of Switching From Cigarette Smoking to THS on Disease Progression in Mild to Moderate COPD Subjects With Chronic Bronchitis Symptoms.	Terminated	N/A	715	Europe, Japan, US, RoW	THS use, Tobacco Heating System 3.0, Cigarette, Smoking Abstinence	Philip Morris Products S.A.	COPD, Smoking, Tobacco Use	09/24	09/24